Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 7Other hematologic neoplasm 3Genitourinary 3Plasma cell 2Dermatologic 2CNS 2Thoracic 1Myeloid 1Breast 1

Conditions

Neuroblastoma 1Neoplasms, Nerve Tissue 1Neoplasms 1Glioma 1Glioblastoma 1

Interventions

Temozolomide 610Radiotherapy 388Bevacizumab 254Magnetic Resonance Spectroscopy 203Cyclophosphamide 177Carboplatin 159Radiosurgery 146Etoposide 132Radiation 121Irinotecan 115Vincristine 114Cisplatin 102Filgrastim 100Specimen Handling 88Nivolumab 87pembrolizumab 82Lomustine 81Topotecan 73Surgical Procedures, Operative 73Doxorubicin 60Melphalan 59Carmustine 57sargramostim 53Radiotherapy, Intensity-Modulated 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 50Erlotinib Hydrochloride 50Everolimus 48Chemotherapy, Adjuvant 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × keyhole-limpet hemocyanin × CNS × Clear all
NCT02754362 2020-01-13

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

NYU Langone Health

Phase 2 Withdrawn
CNS

Glioblastoma, Glioma

NCT02745756 2017-08-30

A Combined Cell Therapy Approach to the Treatment of Neuroblastoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Withdrawn
CNS

Neoplasms, Neoplasms, Nerve Tissue, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡